Relative bioavailability of three formulations of galunisertib administered as monotherapy in patients with advanced or metastatic cancer

OBJECTIVE: Galunisertib (LY2157299 monohydrate), an inhibitor of the transforming growth factor β (TGFβ) pathway, is currently under investigation in several clinical trials involving multiple tumor types. The primary objective of this study was to assess relative bioavailability of two new galunise...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Drugs Context
Autors principals: Gueorguieva, Ivelina, Cleverly, Ann, Desaiah, Durisala, Azaro, Analia, Seoane, Joan, Braña, Irene, Sicart, Elisabet, Miles, Colin, Lahn, Michael M, Mitchell, Malcolm I, Rodon, Jordi
Format: Artigo
Idioma:Inglês
Publicat: Just Medical Media Limited 2016
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5147053/
https://ncbi.nlm.nih.gov/pubmed/27990167
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7573/dic.212303
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars